Cargando…
Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report
Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901600/ https://www.ncbi.nlm.nih.gov/pubmed/35273594 http://dx.doi.org/10.3389/fimmu.2022.799026 |
_version_ | 1784664400126279680 |
---|---|
author | Shao, Jie Liu, Qin Shen, Jie Qian, Xiaoping Yan, Jing Zhu, Yahui Qiu, Xin Lu, Changchang Cen, Lanqi Tian, Manman Du, Juan Liu, Baorui |
author_facet | Shao, Jie Liu, Qin Shen, Jie Qian, Xiaoping Yan, Jing Zhu, Yahui Qiu, Xin Lu, Changchang Cen, Lanqi Tian, Manman Du, Juan Liu, Baorui |
author_sort | Shao, Jie |
collection | PubMed |
description | Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from this treatment. We established a process that includes comprehensive identification of individual mutations, computational prediction of new epitopes, and design and manufacture of unique nanovaccines for this patient. Nanovaccine started after a relapse in third-line treatment. We assessed the patient’s clinical outcome and circulating immune response. In this advanced pancreatic cancer patient, the OS associated with the vaccine treatment was 10.5 months. A peptide-specific T-cell response against 9 of the 12 vaccine peptides could be detected sequentially. Robust neoantigen-specific T cell responses were also detected by IFN-γ ELISPOT and intracellular cytokine staining. In conclusion, sustained functional neoantigen-specific T cell therapy combined with immune checkpoint targeting may be well suited to help control progressive metastatic pancreatic cancer. |
format | Online Article Text |
id | pubmed-8901600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89016002022-03-09 Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report Shao, Jie Liu, Qin Shen, Jie Qian, Xiaoping Yan, Jing Zhu, Yahui Qiu, Xin Lu, Changchang Cen, Lanqi Tian, Manman Du, Juan Liu, Baorui Front Immunol Immunology Personal neoantigen vaccines are considered to be effective methods for inducing, amplifying and diversifying antitumor T cell responses. We recently conducted a clinical study that combined neoantigen nanovaccine with anti-PD-1 antibody. Here, we reported a case with a clear beneficial outcome from this treatment. We established a process that includes comprehensive identification of individual mutations, computational prediction of new epitopes, and design and manufacture of unique nanovaccines for this patient. Nanovaccine started after a relapse in third-line treatment. We assessed the patient’s clinical outcome and circulating immune response. In this advanced pancreatic cancer patient, the OS associated with the vaccine treatment was 10.5 months. A peptide-specific T-cell response against 9 of the 12 vaccine peptides could be detected sequentially. Robust neoantigen-specific T cell responses were also detected by IFN-γ ELISPOT and intracellular cytokine staining. In conclusion, sustained functional neoantigen-specific T cell therapy combined with immune checkpoint targeting may be well suited to help control progressive metastatic pancreatic cancer. Frontiers Media S.A. 2022-02-22 /pmc/articles/PMC8901600/ /pubmed/35273594 http://dx.doi.org/10.3389/fimmu.2022.799026 Text en Copyright © 2022 Shao, Liu, Shen, Qian, Yan, Zhu, Qiu, Lu, Cen, Tian, Du and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Shao, Jie Liu, Qin Shen, Jie Qian, Xiaoping Yan, Jing Zhu, Yahui Qiu, Xin Lu, Changchang Cen, Lanqi Tian, Manman Du, Juan Liu, Baorui Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title_full | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title_fullStr | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title_full_unstemmed | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title_short | Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report |
title_sort | advanced pancreatic cancer patient benefit from personalized neoantigen nanovaccine based immunotherapy: a case report |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901600/ https://www.ncbi.nlm.nih.gov/pubmed/35273594 http://dx.doi.org/10.3389/fimmu.2022.799026 |
work_keys_str_mv | AT shaojie advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT liuqin advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT shenjie advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT qianxiaoping advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT yanjing advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT zhuyahui advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT qiuxin advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT luchangchang advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT cenlanqi advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT tianmanman advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT dujuan advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport AT liubaorui advancedpancreaticcancerpatientbenefitfrompersonalizedneoantigennanovaccinebasedimmunotherapyacasereport |